0 results available. Select is focused ,type to refine list, press Down to open the menu,
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs for ad...
The following section summarizes insights on Laurus Labs Ltd's EV / EBITDA:
We've identified the following companies as similar to Laurus Labs Ltd because they operate in a related industry or sector. We also considered size, growth, and various financial metrics to narrow down the list to the ones listed below.
To view the full list of supported financial metrics please see Complete Metrics Listing.
Metrics similar to EV / EBITDA in the valuation category include:
Measures the dollars in Enterprise Value for each dollar of EBITDA over the last twelve months.
LTM EBITDA Multiple is defined as:
EBITDA Multiple = Enterprise Value / LTM EBITDA
Applying this formula, Laurus Labs’s EV/EBITDA Ratio is calculated below:
Enterprise Value [ ₹354.2 B ]
(/) EBITDA [ ₹10.553 B ]
(=) EV/EBITDA Ratio [ 33.6x ]
The tables below summarizes the trend in Laurus Labs’s EV/EBITDA Ratio over the last five years:
| Date | Enterprise Value | EBITDA | EV/EBITDA Ratio |
|---|---|---|---|
| 2021-03-31 | ₹203.5 B | ₹12.802 B | 15.9 |
| 2022-03-31 | ₹334.4 B | ₹14.759 B | 22.7 |
| 2023-03-31 | ₹178.3 B | ₹16.702 B | 10.7 |
| 2024-03-31 | ₹232.3 B | ₹8.45 B | 27.5 |
| 2025-03-31 | ₹354.2 B | ₹10.553 B | 33.6 |
EBITDA Multiple, Enterprise Value / EBITDA, or EV / EBITDA measures the dollars in Enterprise Value for each dollar of EBITDA.
EBITDA is used in the denominator since it is capital structure neutral and can be used to compare companies with different levels of debt (See EBITDA for benefits). We use Enterprise Value as the numerator to consider the claims on EBITDA of both debt and equity holders.
Strong revenue and EBITDA growth are highly correlated with higher EBITDA Multiples.
Read more about enterprise value (ev) and ebitda
The chart above depicts the distribution of ev / ebitda for companies operating in the Healthcare sector in the Developing economic region. Over 1,150 companies were considered in this analysis, and 1,105 had meaningful values. The average ev / ebitda of companies in the sector is 13.6x with a standard deviation of 35.7x.
Laurus Labs Ltd's EV / EBITDA of 33.6x ranks in the 84.3% percentile for the sector. The following table provides additional summary stats:
| Economic Risk Region | Developing |
| Total Constituents | 1,151 |
| Included Constituents | 1,105 |
| Min | -163.5x |
| Max | 207.8x |
| Median | 12.9x |
| Mean | 13.6x |
| Standard Deviation | 35.7x |
You can find companies with similar ev / ebitda using this stock screener.